![]() Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. ![]() Thielen N, Visser O, Ossenkoppele G, Janssen J. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.Ĭhronic myeloid leukemia European LeukemiaNet National comprehensive cancer network Treatment-free remission Tyrosine kinase inhibitors.īower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. ![]() CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). ![]() Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |